The FDA approved Ultragenyx Pharmaceutical’s Fayuvi (rebisufligene etisparvovec-hopf), the first treatment for children with ...
Trust in the pharma industry has been steadily declining among consumers, regardless of political affiliation. A 2023 study ...
Voters will weigh in on abortion in Missouri, and three other states, in the November general election. Missouri is also one ...
The multiyear deal embeds real-time pricing into Epocrates' drug content. Executives call the launch a baseline and pitch it ...
In this episode, industry leaders from Syneos Health, Joe Daley and Matthew Snodgrass, introduce a new definition of success ...
About half of rural American voters believe the economy is worse off now than when President Donald Trump returned to office, ...
Hundreds of marketing, comms and advertising pros will join us in New York City on November 12. You’ll want to be among them.
For Hispanic Heritage Month, marketing leaders from Cologuard and MetroPlusHealth explain why culturally relevant healthcare ...
Investors eye osteoporosis; Bipartisan scrutiny of drugmakers, insurers and PBMs; U.S. scales back ACA coverage.
The drugmaker designed “Because Ibsrela Can” with clear, static safety visuals after studying the agency’s recent objections ...
Moran referred to “change fatigue” at a morning panel that also featured 2025 MM+M Awards jury chair Meghan Rivera, VP, ...
When targeted cancer treatment is available but coverage isn’t; Novo invests further in childhood obesity prevention; Roche’s ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results